FindTrial
Sign In

SX-682

DRUG9 trials

Sponsors

Syntrix Biosystems, Inc., University of Rochester, National Cancer Institute (NCI), Lei Zheng, Institute of Cancer Research, United Kingdom

Conditions

Adenoid Cystic CarcinomaCarcinoma of LarynxHead and Neck CancerHead and Neck Squamous Cell CarcinomaHypopharyngeal CancerMelanoma Stage IIIMelanoma Stage IVMetastatic Cancer

Phase 1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Active, not recruitingNCT03161431
Syntrix Biosystems, Inc.Melanoma Stage III, Melanoma Stage IV
Start: 2019-06-12End: 2027-06-30Target: 77Updated: 2025-12-23
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
RecruitingNCT04245397
Syntrix Biosystems, Inc.Myelodysplastic Syndromes
Start: 2020-06-30End: 2029-03-31Target: 151Updated: 2025-12-23
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Active, not recruitingNCT04477343
University of RochesterPancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Start: 2020-11-23End: 2026-12-31Target: 20Updated: 2026-07-06
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta Trap/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
CompletedNCT04574583
National Cancer Institute (NCI)Metastatic Cancer, Solid Tumors
Start: 2020-11-24End: 2023-05-19Updated: 2025-02-03
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RecruitingNCT06149481
National Cancer Institute (NCI)Metastatic Colorectal Cancer
Start: 2024-03-26End: 2030-10-31Target: 60Updated: 2026-07-13
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
RecruitingNCT07002320
Institute of Cancer Research, United KingdomMetastatic Castrate-Resistant Prostate Cancer (mCRPC)
Start: 2025-04-28End: 2029-10-01Target: 78Updated: 2026-04-15
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Not yet recruitingNCT07667400
National Cancer Institute (NCI)Adenoid Cystic Carcinoma, Carcinoma of Larynx, Head and Neck Cancer +9
Start: 2026-07-23End: 2037-10-01Target: 120Updated: 2026-07-20

Phase 2

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Active, not recruitingNCT05604560
Lei ZhengPancreatic Cancer
Start: 2023-11-08End: 2026-09-30Target: 25Updated: 2025-07-23
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
RecruitingNCT06228053
Syntrix Biosystems, Inc.Metastatic Castration-resistant Prostate Cancer
Start: 2024-11-18End: 2028-06-30Target: 53Updated: 2026-06-02

Related Papers

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.
Journal of Clinical Oncology2024-06-0113 citations
Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
Blood2022-11-1512 citations
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
Journal of Clinical Oncology2022-01-199 citations